Ochronosis: Difference between revisions
Brian Blank (talk | contribs) No edit summary |
Rim Halaby (talk | contribs) No edit summary |
||
| (3 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{SI}} | |||
{{CMG}} | |||
}} | |||
==Overview== | ==Overview== | ||
'''Ochronosis''' is a dermatological disorder that results in the adverse pigmentation of cartilage from a long term buildup of [[phenylalanine]] or [[tyrosine]]. | '''Ochronosis''' is a dermatological disorder that results in the adverse pigmentation of cartilage from a long term buildup of [[phenylalanine]] or [[tyrosine]]. | ||
| Line 43: | Line 30: | ||
{{Endocrine, nutritional and metabolic pathology}} | {{Endocrine, nutritional and metabolic pathology}} | ||
[[fr:Ochronose]] | [[fr:Ochronose]] | ||
[[pl:Ochronoza]] | [[pl:Ochronoza]] | ||
{{WikiDoc Help Menu}} | |||
{{WikiDoc Sources}} | |||
[[Category: | [[Category:Disease]] | ||
[[Category:Genetic Disease]] | [[Category:Genetic Disease]] | ||
[[Category:Inborn errors of metabolism]] | [[Category:Inborn errors of metabolism]] | ||
Latest revision as of 20:02, 20 November 2013
|
WikiDoc Resources for Ochronosis |
|
Articles |
|---|
|
Most recent articles on Ochronosis |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Ochronosis at Clinical Trials.gov Clinical Trials on Ochronosis at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Ochronosis
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Ochronosis Discussion groups on Ochronosis Patient Handouts on Ochronosis Directions to Hospitals Treating Ochronosis Risk calculators and risk factors for Ochronosis
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Ochronosis |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Ochronosis is a dermatological disorder that results in the adverse pigmentation of cartilage from a long term buildup of phenylalanine or tyrosine.
In this disorder, a pigment substance resulting from incomplete catabolism of tyrosine and phenylalanine is deposited, over the years, in cartilage, the eye, and to a lesser degree in the skin.
Symptoms
Pigmented cartilage may appear blue due to scattering phenomenon, and to a lesser degree this may be true for skin with dermal deposition of this pigment. The skin of the axilla is very likely to be pigmented due to deposits of homogentisic acid in sudoriferous glands in these areas. The clinical features of this metabolic disorder are dark urine, pigmentation of the skin and arthritis. Particularly helpful is the almost constant presence of a patch of pigmentation (gray to brown in color) in the sclera, between the margin of the cornea and the outer or inner canthus. Because of the bluish color produced by the deep pigmentation, this condition may be confused with argyria.
See also
References
- Jeghers, H. (1944). "Pigmentation of the skin". N Engl J Med. 231.
- The University of Massachusetts Online Article on Skin Pigmentation Disorders [2]